dcsimg Aranesp® (darbepoetin alfa) – Risk for Transfusion
› Email› Print

Risk for transfusion progressively increased
the longer Hb remained < 10 g/dL1

Risk for Transfusion

Increased risk for transfusion remained even after adjusting for clinical factors such as age, race, and comorbidities.

Monitor Hb frequently and intervene with Aranesp® to reduce the need for RBC transfusions.2

Important Safety Information

  • Use caution in patients with coexistent cardiovascular disease and stroke.
  • Patients with CKD and an insufficient hemoglobin response to ESA therapy may be at even greater risk for cardiovascular reactions an mortality than other patients. A rate of hemoglobin rise of > 1 g/dL over 2 weeks may contribute to these risks.

Scroll down for additional
Important Safety Information.

Abbreviations and References:
ESA = erythropoiesis-stimulating agent; RBC = red blood cell; Hb = hemoglobin.
References: 1. Gilbertson DT, Monda KL, Bradbury BD, Collins AJ. RBC transfusions among hemodialysis patients (1999-2010): influence of hemoglobin concentrations below 10 g/dL. Am J Kidney Dis. 2013;62:919-928. 2. Aranesp® (darbepoetin alfa) prescribing information, Amgen.

Biotechnology by Amgen®